UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 650

Sortiert nach

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

Journal of hematology and oncology, 2021-06, Vol.14 (1), p.102-102, Article 102

2021

Volltextzugriff (PDF)

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

Journal of clinical oncology, 2014-11, Vol.32 (31), p.3497-3505

2014

Volltextzugriff (PDF)

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review

Expert opinion on drug metabolism & toxicology, 2017-09, Vol.13 (9), p.901-923

2017

Volltextzugriff (PDF)

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Blood, 2015-05, Vol.125 (19), p.2885-2892

2015

Volltextzugriff (PDF)

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Journal of hematology and oncology, 2023-10, Vol.16 (1), p.108-108, Article 108

2023

Volltextzugriff (PDF)

Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study

Bone marrow transplantation (Basingstoke), 2019-11, Vol.54 (11), p.1799-1804

2019

Volltextzugriff (PDF)

Autologous engineered T cell receptor therapy in advanced cancer

Human vaccines & immunotherapeutics, 2023-12, Vol.19 (3), p.2290356-2290356

2023

Volltextzugriff (PDF)

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Haematologica (Roma), 2017-01, Vol.102 (1), p.110

2017

Volltextzugriff (PDF)

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

Pharmacogenomics, 2013-01, Vol.14 (1), p.75-87

2013

Volltextzugriff (PDF)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study

Haematologica (Roma), 2022-10, Vol.107 (10), p.2496

2022

Volltextzugriff (PDF)

Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells

Frontiers in oncology, 2023, Vol.13, p.1287444-1287444

2023

Volltextzugriff (PDF)

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Blood, 2004-08, Vol.104 (3), p.865-872

2004

Volltextzugriff (PDF)

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Blood, 2004-08, Vol.104 (3), p.857-864

2004

Volltextzugriff (PDF)

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Acta haematologica, 2021-01, Vol.144 (1), p.74-81

2021

Volltextzugriff (PDF)

Steroid-Refractory Acute GVHD: Predictors and Outcomes

Advances in Hematology, 2011, Vol.2011, p.601953-8

2011

Volltextzugriff (PDF)

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Blood, 2003-10, Vol.102 (8), p.3052-3059

2003

Volltextzugriff (PDF)

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications

Experimental hematology, 2013-08, Vol.41 (8), p.719-730

2013

Volltextzugriff (PDF)

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture

The New England journal of medicine, 2012-12, Vol.367 (24), p.2305-2315

2012

Volltextzugriff (PDF)

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs

Oncotarget, 2022-10, Vol.13 (1), p.1122-1135

2022

Volltextzugriff (PDF)

Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells

Leukemia & lymphoma, 2022-06, Vol.63 (7), p.1634-1644

2022

Volltextzugriff (PDF)

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells

Oncotarget, 2022, Vol.13 (1), p.319-330

2022

Volltextzugriff (PDF)

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells

Oncotarget, 2024-03, Vol.15 (1), p.220-231

2024

Volltextzugriff (PDF)

Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study

Journal of clinical oncology, 2011-01, Vol.29 (3), p.294-302

2011

Volltextzugriff (PDF)

1 – 25 von 650

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(496)
Mit Volltextzugriff
(585)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(292)
Humans
(260)
Life Sciences & Biomedicine
(251)
Male
(143)
Female
(140)
Middle Aged
(135)
Hematology
(132)
Adult
(118)
Biological And Medical Sciences
(92)
Medical Sciences
(89)
Aged
(83)
Transplantation
(81)
Oncology
(77)
Immunology
(76)
Hematology, Oncology And Palliative Medicine
(73)
Adolescent
(52)
Hematopoietic Stem Cell Transplantation
(52)
Transplantation, Homologous
(49)
Treatment Outcome
(46)
Pharmacology. Drug Treatments
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning

Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review

Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation

Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide

Pharmacokinetics analysis results are similar for oral compared to intravenous busulfan in patients undergoing hematopoietic stem cell transplantation, except for the earlier onset of mucositis. A controlled clinical study

Autologous engineered T cell receptor therapy in advanced cancer

Pre-transplantation minimal residual disease with cytogenetic and molecular diagnostic features improves risk stratification in acute myeloid leukemia

Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation

Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study

Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells

Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation

Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS

Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia

Steroid-Refractory Acute GVHD: Predictors and Outcomes

Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years

Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications

Cord-Blood Engraftment with Ex Vivo Mesenchymal-Cell Coculture

HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs

Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells

ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells

Prophylaxis of Graft-Versus-Host Disease in Unrelated Donor Transplantation With Pentostatin, Tacrolimus, and Mini-Methotrexate: A Phase I/II Controlled, Adaptively Randomized Study

Suchergebnisse filtern